Bildkälla: Stockfoto

Chromogenics: First take – Q4’22 - Redeye

Redeye states that Chromogenics Q4 report was weak on topline with higher OPEX

Redeye states that Chromogenics Q4 report was weak on topline with higher OPEX
Börsvärldens nyhetsbrev
ANNONSER